[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532746":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":60,"collaborators":26,"id":64,"slug":26,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":26,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Shenyang Northern Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard DAPT therapy","ACTIVE_COMPARATOR","Standard DAPT therapy for 12 mouths",[13],"Drug: standard DAPT",{"label":15,"type":16,"description":17,"interventionNames":18},"OPT-CAD score guided de-escalation DAPT therapy","EXPERIMENTAL","Patients at moderate to high risk of ischemic events assessed by the OPT-CAD score will receive DAPT therapy for 3 months followed by P2Y12 inhibitor monotherapy for 9 months; Patients at low risk of ischemic events assessed by the OPT-CAD score will receive DAPT for 1 month follow by P2Y12 inhibitor monotherapy for 11 months.",[19],"Drug: OPT-CAD score guided DAPT de-escalation",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","standard DAPT","standard DAPT with aspirin and a P2Y12 inhibitor for 12 months after DES implantation.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"OPT-CAD score guided DAPT de-escalation","De-escalation DAPT at 3 months for moderate to high risk patients and de-escalation DAPT at 1 month for low risk patients.",[15],[32],{"name":33,"affiliation":34,"role":35},"Yaling Han, PhD","The General Hospital of Northern Theater Command","STUDY_CHAIR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Yi Li, PhD","CONTACT","+86-24-28897309","doctorliyi@126.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"General Hospital of Northern Theater Command","RECRUITING","Shenyang","Liaoning","110016","China","CN",{"type":52,"coordinates":53},"Point",[54,55],123.43278,41.79222,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":40,"phoneExt":26,"email":41},"Yi Li, MD",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Yi Li","Professor","100532746",false,"NCT06216821","OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time","OPT-CAD Score Guided Dual Antiplatelet De-escalation Time in Patients With Acute Coronary Syndrome Undergoing Undergoing Percutaneous Coronary Intervention: a Register-based Randomized Controlled Study","OPT-GUIDNACE","Inclusion Criteria:\n\n1. Adult patients with ages of 18-80 years;\n2. Patients with clinically diagnosed ACS who have undergone at least one DES implantation;\n3. Individuals capable of completing the OPT-CAD scoring calculation;\n4. Researchers assessing that participants can tolerate at least a 12-month duration of DAPT therapy;\n5. Written informed consent provided.\n\nExclusion Criteria:\n\n1. Left main coronary artery lesion PCI;\n2. Allergy to study drugs such as aspirin, clopidogrel, or ticagrelor;\n3. Meeting 1 major or 2 minor criteria for high bleeding risk according to the ARC-HBR criteria;\n4. Anticipated need for revascularization or surgical intervention within 12 months;\n5. Severe ischemia or hemorrhage events during the current hospitalization;\n6. Life expectancy of other serious diseases is less than 1 year;\n7. Pregnant or women of childbearing age who intend to conceive within 1 year;\n8. Participation in other clinical trials while still under observation;\n9. Researchers considering ineligibility for enrollment.","ALL","18 Years","80 Years",{"count":75,"type":76},3490,"ESTIMATED","INTERVENTIONAL",[79],"NA","Monotherapy with a P2Y12 inhibitor after a minimum period of DAPT following percutaneous coronary intervention (PCI) is an emerging de-escalation antiplatelet strategy in recent years. However, the optimal timing for de-escalating DAPT in ACS patients undergoing PCI remains debated. The OPT-CAD score is a risk stratification tool derived from Chinese patients which has been demonstrated superior predictive capabilities for ischemic events and all-cause mortality than the GRACE score. Therefore, we hypothesize that the OPT-CAD score can be used to guide the timing of the DAPT de-escalation strategy to monotherapy with P2Y12 inhibitors for ACS patients, that is, low-risk patients could be de-escalated after 1 month, while high-risk patients could be de-escalated after 3 months, so as to achieve individualized antithrombotic therapy and maximize patient benefit.",[82],"Acute Coronary Syndrome","2025-09-03",{"date":85,"type":86},"2025-09-10","ACTUAL",{"date":88,"type":86},"2024-07-02",{"date":90,"type":76},"2027-12-31",{"name":5,"class":6},1]